Ionis reveals encouraging preliminary outcomes from the third phase of the OASIS-HAE trial, examining the experimental compound donidalorsen in individuals with genetic angioedema.

In the CheckMate -8HW study, the combination of Opdivo and Yervoy reduced the likelihood of disease advancement or fatality in patients with MSI-H/dMMR metastatic colorectal cancer by 79% when compared to chemotherapy.

BALVERSA® gains complete sanction from the U.S. FDA to cure bladder cancer in advanced or metastatic stages with specific genetic changes.

Novartis Lutathera® substantially lessens the risk of gastroenteropancreatic neuroendocrine tumors worsening or mortality by 72%.

At the 2024 ASCO GI Cancers Symposium, CARsgen Therapeutics presented study results for "satri-cel" (CT041), a Claudin18.2-targeted CAR-T therapy.

Durvalumab (IMFINZI®) combined with transarterial chemoembolization (TACE) and bevacizumab lowered the chance of liver cancer progression or death by 23%.

At the 2024 ASCO GI Cancers Symposium, Coherus showcased encouraging Phase 2 trial results for Casdozokitug, an innovative IL-27-targeted antibody.

AEON Biopharma Shares Positive Data on ABP-450 Treatment for Cervical Dystonia and PTSD at Neurotoxin Conference.

Vor Bio Commences Treatment on Initial Patient with Acute Myeloid Leukemia Using VCAR33 (ALLO) and Shares Company Progress Update.

Evommune Reveals Launch of an Early-Stage Study for Its Novel MRGPRX2 Inhibitor Aimed at Managing Persistent Idiopathic Hives.

PeproMene Bio Announces First Patient in Cohort 1 Achieves Complete Remission in B-ALL Phase 1 Trial with PMB-CT01 at City of Hope.

Immunity Pharma, a clinical-stage neurology specialist, announced positive initial results from its Phase 2a IPL344 trial in ALS patients.